SEI Investments
ANIP icon

SEI Investments’s ANI Pharmaceuticals ANIP Stock Holding History

SEI Investments’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.57M Sell
43,157
-14,011
-25% -$1.12M ﹤0.01% 1660
2026
Q1 		$4.4M Buy
57,168
+15,367
+37% +$1.2M ﹤0.01% 1605
2025
Q4 		$3.3M Buy
41,801
+18,382
+78% +$1.59M ﹤0.01% 1595
2025
Q3 		$2.14M Buy
23,419
+14,753
+170% +$1.2M ﹤0.01% 1671
2025
Q2 		$565K Sell
8,666
-1,375
-14% -$89.5K ﹤0.01% 2129
2025
Q1 		$672K Sell
10,041
-12,733
-56% -$761K ﹤0.01% 2041
2024
Q4 		$1.26M Buy
22,774
+2,752
+14% +$158K ﹤0.01% 1845
2024
Q3 		$1.19M Buy
20,022
+5,549
+38% +$339K ﹤0.01% 1887
2024
Q2 		$922K Buy
14,473
+3,152
+28% +$205K ﹤0.01% 1938
2024
Q1 		$783K Buy
11,321
+1,594
+16% +$96.2K ﹤0.01% 1976
2023
Q4 		$536K Buy
+9,727
New +$536K ﹤0.01% 2082
2023
Q3 		– Sell
-12,568
Closed -$677K – 2623
2023
Q2 		$677K Sell
12,568
-3,389
-21% -$150K ﹤0.01% 2022
2023
Q1 		$634K Buy
15,957
+4,099
+35% +$173K ﹤0.01% 2046
2022
Q4 		$477K Buy
+11,858
New +$445K ﹤0.01% 2023
2019
Q3 		– Sell
-2,531
Closed -$206K – 2368
2019
Q2 		$206K Sell
2,531
-43
-2% -$3.06K ﹤0.01% 2243
2019
Q1 		$178K Buy
2,574
+1,542
+149% +$90.7K ﹤0.01% 2323
2018
Q4 		$55K Buy
1,032
+253
+32% +$13.3K ﹤0.01% 2319
2018
Q3 		$43K Sell
779
-2,007
-72% -$123K ﹤0.01% 2261
2018
Q2 		$186K Buy
2,786
+534
+24% +$33.3K ﹤0.01% 2086
2018
Q1 		$131K Buy
2,252
+817
+57% +$51.9K ﹤0.01% 2038
2017
Q4 		$93K Sell
1,435
-186
-11% -$11.6K ﹤0.01% 2166
2017
Q3 		$85K Buy
1,621
+464
+40% +$22.1K ﹤0.01% 2129
2017
Q2 		$55K Buy
1,157
+402
+53% +$19.4K ﹤0.01% 2224
2017
Q1 		$38K Buy
755
+330
+78% +$18.5K ﹤0.01% 2194
2016
Q4 		$25K Buy
425
+118
+38% +$7.21K ﹤0.01% 2291
2016
Q3 		$21K Buy
307
+267
+668% +$16.7K ﹤0.01% 2263
2016
Q2 		$2K Buy
+40
New +$1.94K ﹤0.01% 2468
2015
Q4 		– Sell
-2,100
Closed -$83K – 2522
2015
Q3 		$83K Buy
+2,100
New +$119K ﹤0.01% 1825

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SEI Investments's ANIP Position: Q2 2026 in Review

SEI Investments reduced its ANI Pharmaceuticals (ANIP) stake by 25% in Q2 2026, selling an estimated $1.12M and leaving 43,157 shares worth $3.57M. The position accounts for ﹤0.01% of the portfolio, ranked #1660.

SEI Investments first reported a position in ANIP in Q3 2015 and has held it in 28 quarters since. The position peaked at $4.4M in Q1 2026. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • SEI Investments held 43,157 shares of ANI Pharmaceuticals worth $3.57M as of Q2 2026.
  • SEI Investments sold 14,011 ANI Pharmaceuticals shares in Q2 2026, an estimated $1.12M.
  • ANI Pharmaceuticals made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #1660 holding.
  • SEI Investments first reported a position in ANI Pharmaceuticals in Q3 2015 and has held it in 28 quarters since.
  • SEI Investments's ANI Pharmaceuticals position peaked at $4.4M in Q1 2026.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.